CJC-1295 vs Hexarelin
A side-by-side research comparison of CJC-1295 and Hexarelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | Hexarelin |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Hexarelin (Examorelin) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Potent GHSR-1a agonist producing maximal pituitary GH output. Additionally binds cardiac CD36, providing cardioprotection through anti-apoptotic mechanisms independent of GH. |
| Molecular weight | 3,368 Da (without DAC) | 887 Da |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | 1-2 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-300 mcg | 100-200 mcg |
| Frequency | 1-3x daily (no-DAC) | 2-3x daily |
| Route | Subcutaneous injection | Subcutaneous |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
Hexarelin reported benefits
- Strongest GH release
- Cardioprotective effects
- Recovery acceleration
- Anti-fibrotic (cardiac)
- Neuroprotective potential
Related comparisons
Research and educational reference only. Not medical advice.